Category: Monkey Pox Vaccine

Toronto Public Health will begin hosting a series of clinics to provide "low-barrier, convenient and equitable access" to mpox vaccinations on Wednesday.

According to TPH, 21 cases of mpox have been confirmed in Toronto since the start of this year, compared with a total of 27 cases for all of 2023.

The city is encouraging eligible residents to get vaccinated against the virus.

The first clinic on Wednesday will be available for walk-in appointments only, from 10 a.m. to 5 p.m. at The 519, a community centre at 519 Church Street.

The second clinic will run on Saturday from 10 a.m. to 2 p.m. at . This clinic will not accept walk-ins and eligible residents will need to book appointments using TPHs online booking system.

The city will announce additional clinic locations, dates, and times on their website as they become available.

Additionally, eligible residents can receive the vaccine by appointment at the Crosswaysand Scarborough Sexual Health Clinics.

The vaccine is free of charge, and an OHIP card is not required. Residents can also inquire about vaccine availability where they currently access sexual healthcare services, according to TPH.

The public health unit said the virus has recently spread mostly between people who have had intimate or sexual contact, with men who have sex with men being the most affected.

The virus spreads through contact with infected lesions, skin blisters, body fluids or respiratory secretions.

Symptoms can start five to 21 days after exposure and include fever, headache, muscle aches, exhaustion, swollen lymph nodes and a rash or blisters and lesions on the skin.

Individuals who are members of the LGBTQ+ community who had a confirmed sexually transmitted infection, have or are planning to have two or more sexual partners, or have attended venues for sexual contact such as sex clubs are among those eligible to receive the mpox vaccine.

Eligible individuals who have not been vaccinated against mpox are encouraged to get their first dose of the vaccine as soon as possible, with a second dose given at least 28 days later, TPH said, adding that individuals planning to travel soon are encouraged to get vaccinated before leaving, as cases are being reported in various regions around the world. They say, the vaccine becomes most effective after two weeks.

The monkeypox disease comes from the same family of viruses that cause smallpox, which the World Health Organization declared eradicated around the globe in 1980. Smallpox vaccines have proven effective in combating the monkeypox virus.

With files from The Canadian Press

See the original post:

Toronto hosting free mpox vaccination clinics. Here's where they are being held - Toronto Star

The number of mpox cases in 2024 is already nearly double the number of cases that were detected in all of 2023.

The most recent data from the Centers for Disease Control and Prevention (CDC) has recorded 582 cases of mpox, formerly known as monkeypox, across all U.S. states and territories in 2024 to date. In 2023, a cumulative 299 cases were detected across the entire year.

The Middle Atlantic region New Jersey, New York, and Pennsylvania is currently reporting the highest number at 185 cases.

Mpox surged in the U.S. during 2022 when cases spread through the social networks of men who have sex with men. In the U.S., more than 32,000 cases of mpox were detected that year along with 58 total deaths.

The outbreak subsided through outreach and awareness as well as the use of the two-dose smallpox vaccine Jynneos, though access to this shot was hindered at first by limited supplies and poor planning.

Symptoms of the virus are flu-like and include a characteristic painful rash. It is primarily spread through skin contact, but unwashed clothing and bedsheets of an infected individual can also be a vector of transmission.

The public health emergency declaration for the mpox outbreak was allowed to expire in January 2023. Cases of mpox never quite reached zero, however, with the virus continuing to linger in the U.S.

There were concerns last year that a localized spread of mpox cases in Chicago could be the harbinger of a summer resurgence last May, though this ultimately didnt occur.

Bavarian Nordic, the manufacturer of Jynneos, announced Tuesday that its vaccine would now be commercially available in the U.S.

Through its existing nationwide vaccine distribution structure, Bavarian Nordic is now making the mpox vaccine commercially available across the nation. As of April 1, health care providers can order JYNNEOS through their preferred wholesaler and distribution partners to make it available for at-risk individuals at local pharmacies and physician offices in addition to public health clinics, the company said in a statement.

For the latest news, weather, sports, and streaming video, head to The Hill.

Read the original here:

Mpox infections rise to almost double last year's numbers - AOL

There have been 21 cases of monkeypox in Toronto so far this year, almost reaching the total number of cases reported in 2023.

Toronto Public Health (TPH) released a statement yesterday reminding residents to get vaccinated against mpox amid the rise in local cases. In 2023, there were a total of 27 confirmed cases of the virus in Toronto.

The virus spreads between people through contact with infected lesions, skin blisters, body fluids or respiratory secretions, according to the health agency. It can also be transmitted by contact with contaminated materials like clothing or bedding and through bites or scratches from infected animals.

Currently, mpox has spread mostly between people who have had close/intimate or sexual contact with a person who has the virus with gay, bisexual and other men who have sex with men being most affected, TPH said in a news release.

The agency adds that travel is not a significant factor among current cases in the city, which suggests local community transmission of the virus.

None of the current cases were fully vaccinated, emphasizing the importance of starting or completing the two-dose vaccine series for the best protection, TPH added.

Mpox symptoms can start five to 21 days after exposure and include fever, headache, muscle aches, exhaustion, swollen lymph nodes, and a rash or painful blisters and lesions on the skin including around the genitals.

Eligible individuals who are unvaccinated are encouraged to get their first dose as soon as possible, and a second dose 28 days later.

Vaccination can protect against the mpox virus and help reduce serious symptoms. Individuals who received a smallpox vaccination in the past are not protected against mpox, TPH said.

Residents can inquire about the free vaccine where they access sexual health care. An OHIP card is not required to receive the vaccine.

Continue reading here:

Toronto seeing rise in monkeypox cases; officials urging residents to get vaccinated - NOW Toronto

TORONTO - Twenty one cases of mpox have been confirmed in Toronto since the start of this year compared with a total of 27 cases for all of 2023, Toronto Public Health said on Wednesday.

The public health unit is encouraging eligible residents to get vaccinated against the virus formerly known as monkeypox amid the rise in cases.

It said travel is not a significant factor among the current cases, which suggests local transmission. The public health unit also said none of the affected individuals were fully vaccinated.

"Amidst increased cases of mpox in Toronto, it's important to recognize that cases are predominantly non-travel-related, emphasizing the importance of vaccination," Dr. Eileen de Villa, Toronto's Medical Officer of Health, wrote in a statement.

"Completing the two-dose vaccination series provides the best protection against mpox and helps reduce serious symptoms.

The public health unit said the virus has spread recently mostly between people who have had intimate or sexual contact, with men who have sex with men the most affected.

The virus spreads through contact with infected lesions, skin blisters, body fluids or respiratory secretions.

Symptoms can start five to 21 days after exposure and include fever, headache, muscle aches, exhaustion, swollen lymph nodes and a rash or blisters and lesions on the skin.

Individuals who are members of the LGBTQ+ community who had a confirmed sexually transmitted infection, have or are planning to have two or more sexual partners, or have attended venues for sexual contact such as sex clubs are among those eligible to receive the mpox vaccine.

"We want to remind cis and trans gay, bi, queer, and all men who have sex with men, to get their first and second dose of the mpox vaccine," Devan Nambiar, manager at Gay Mens Sexual Health Alliance wrote in a statement.

"Mpox has not been entirely eradicated and we want you to take care of yourself and protect your sexual partners."

The monkeypox disease comes from the same family of viruses that cause smallpox, which the World Health Organization declared eradicated around the globe in 1980. Smallpox vaccines have proven effective in combating the monkeypox virus.

___

This report by The Canadian Press was first published March 20, 2024.

The Canadian Press. All rights reserved.

Read more:

Toronto reports 21 mpox cases so far this year, after 27 cases in all of 2023 - Toronto Star

Toronto

Share on Facebook Share on Twitter Share by Email

Rochelle Raveendran - CBC News

Posted: March 20, 2024 Last Updated: March 20, 2024

Toronto Public Health (TPH) is advising people to get vaccinated against mpox amidst an increase in confirmed cases of the virus in the city this year.

Twenty-one cases of mpox, previously known as monkeypox, have been reported in Toronto this year, TPH said in a news release on Wednesday.

This is an increase from 2023, where 27 cases were reported for the entire year, according to the news release.

Mpox is a virus that spreads from person to person through contact with infected lesions, skin blisters, body fluids or respiratory secretions, TPH said.

The virus has "spread mostly between people who have had close/intimate or sexual contact with a person who has the virus with gay, bisexual and other men who have sex with men being most affected," TPH said.

None of the current cases in the city were fully vaccinated, TPH said.

Eligible people who have not been vaccinated are encouraged to get their first vaccine dose as soon as possible, with the second dose prescribed 28 days later, the news release said.

The vaccine is free of charge and does not require an OHIP card, TPH said. People are advised to ask about vaccine availability when accessing sexual health care.

Full vaccine eligibility requirements can be found on the City of Toronto website.

Mpox symptoms can start five to 21 days after exposure, and include fever, headache, muscle aches, exhaustion and swollen lymph nodes, the news release said.

"These symptoms are followed by a rash or blisters and lesions on the skin that can be painful including around the genitals," TPH said.

The uptick in mpox cases is not a public health emergency, said Rita Shahin, associate medical officer of health with Toronto Public Health.

"We're not looking at a public health emergency," she said. "We're really seeing a small increase in cases."

Confirmed cases this year are nowhere nearnumbers from 2022, Shahin said, when the city saw over 500 cases of mpox.

"I don't think we're going to be seeing the same kind of explosive case numbers that we saw in 2022, because many of the individuals have had at least one dose," Shahin said.

However, she said people are advised to get their second dose as well.

Shahin said the virus is circulating locally in the city, with only two travel related cases confirmed this year.

"We would like to remind people who are eligible of the importance of getting vaccinated," she said.

The risk of getting mpox is not the same for everybody in Toronto, as the majority of cases are among gay, bisexual and other men who have sex with men, said Dr. Isaac Bogoch, infectious disease specialist at Toronto General Hospital.

"The men who have sex with men community has been heroic in their efforts to educate the local community and to help guide the public health response," Bogoch said.

He described this time period as "an era of emerging and re-emerging infectious diseases," citing the recent rise in measles cases, as well as COVID-19 and both the Zika and Ebola epidemics.

"Many of these [diseases]are preventable," he said. "We can take steps to prevent infection or mitigate severity of infection."

Rochelle Raveendran is a reporter for CBC News Toronto. She can be reached at: rochelle.raveendran@cbc.ca.

More:

Toronto Public Health urges people to get vaccinated against mpox amidst rising cases - CBC.ca

There has been a spike in mpox infections in Toronto since the start of the year and public health officials are now warning eligible residents to make sure they are vaccinated.

The health unit says that since January there have been 21 confirmed cases of the virus in the city, compared to 27 in all of 2023.

In an interview CP24,Associate Medical Officer of Health Dr. Rita Shahin said that most of those who contracted mpox were not immunized against the virus.

"Of the 21 cases that we've seen since January 1, only three of them have had one dose of vaccine and the rest were unimmunized. So it's really an important reminder to people who are at risk that they should get their first dose and followed up with a second dose as well," she said.

"It is a small number of cases and we're not expecting to see the large number of cases that we saw in 2022 with over 500 cases. We know that many eligible people have gotten their first dose of vaccine, but not many came back for a second dose."

The best way to prevent mpox is through a two-dose vaccine that is given over a 28-day period, which protects those immunized against transmission as well as helps reduce serious symptoms of the virus. The vaccine becomes most effective after two weeks, TPS said.

Residents can find out more information about the vaccine, which is free of charge and accessible without an OHIP card, where they access sexual health care.

Shahin said TPH is sharing this latest information in an effort to raise awareness among those who are at the greatest risk of getting mpox and to urge them to get vaccinated.

Public health officials said that currently mpox is primarily being spread in the city between people who have had close/intimate or sexual contact with a person who has the virus. Those most affected include gay and bisexual men as well as men who have sex with other men, Toronto Public Health noted in a release.

"We want to remind cis and trans gay, bi, queer, and all men who have sex with men, to get their first and second dose of the mpox vaccine, Devan Nambiar, of Gay Mens Sexual Health Alliance, said in a release.

Mpox has not been entirely eradicated and we want you to take care of yourself and protect your sexual partners.

Public health officials went on to say that travel is not a significant factor among the current infections, meaning that the majority of the cases being seen in Toronto are the result of local community transmission.

Mpox, which is formerly known as monkeypox, is a virus that spreads from person to person through contact with infected lesions, skin blisters, body fluids, or respiratory secretions. It can also be transmitted through contact with contaminated materials like clothing or bedding as well as through bites or scratches from infected animals.

Symptoms of mpox can begin anywhere from five to 21 days after exposure and include fever, headache, muscle aches, exhaustion, and swollen lymph nodes. Toronto Public Health said that those symptoms are followed by a rash or blisters and lesions on the skin that can be painful, including around the genitals.

More information about mpox, including where to get vaccinated against it, can be found online.

Read the original:

Toronto Public Health reporting spike in mpox infections, residents urged to get vaccinated - CP24

Open this photo in gallery:

A Toronto public health official said she doesn't expect the uptick in mpox cases to lead to the same large outbreak that Canada saw in 2022, but urges people at risk of the virus to get vaccinated.Alain Jocard/The Associated Press

Toronto health officials are sounding the alarm about a rise in mpox cases and are urging anyone who may be at higher risk of contracting the virus to get vaccinated.

So far this year, there have been 21 confirmed cases of the virus, formerly known as monkeypox, in the city, compared with 27 cases in all of 2023.

Only two of this years confirmed mpox cases involved international travel, suggesting that local spread among unvaccinated or under-vaccinated individuals is contributing to the current situation, said Rita Shahin, associate medical officer of health with Toronto Public Health.

The mpox virus, explained: Symptoms, vaccines, spread and more

Mpox cases have been popping up in other jurisdictions, including Ottawa and New York, but less so in Montreal, Dr. Shahin said.

It does seem like theres still small pockets of local transmission in some areas, she said.

Mpox is predominantly spreading among men who have sex with men. People who have more than two sex partners, those who engage in anonymous sex or frequent sex clubs are at higher risk, Dr. Shahin said. The virus can spread person to person through contact with lesions, scabs or bodily fluids.

Mpox can lead to fever, muscle aches, a sore throat and a painful rash or lesions that can be on one part of the body, such as the face or genitals, or spread everywhere. Some individuals may experience serious complications, including bacterial infections, pneumonia, and brain or heart inflammation.

The viruss name was changed to mpox at the World Health Organizations suggestion, after a large outbreak in 2022 that was accompanied by racist and stigmatizing language about the infection.

Dr. Shahin said officials dont expect the uptick in mpox cases to lead to the same large outbreak that Canada saw in 2022, when Ontario reported nearly 700 cases. But she said its important for people who may be at risk to be aware of the situation and to protect themselves.

The mpox vaccine is a two-dose series given 28 days apart. During the 2022 outbreak, many higher risk people received one dose of the vaccine, but only 16 per cent received the second dose. Dr. Shahin said that could be because the outbreak began to wane, lessening the sense of urgency around vaccination.

An analysis published in the Cell journal last month credited a widespread change in behaviour among individuals with bringing the outbreak under control. At the time, vaccines werent readily available, but cases started to wane regardless, which the authors credit to public messaging to higher-risk individuals.

Dr. Shahin said that part of the reason there may be an increase in cases now is that individuals may be returning to higher-risk activities, such as having multiple sex partners.

Were not expecting to see a large outbreak, but its a good reminder for people to think about their sexual health and getting immunized if theyre eligible.

Continued here:

Rise in mpox virus cases prompts alert from Toronto public health officials - The Globe and Mail

DUBLIN, March 19, 2024 /PRNewswire/ -- The "Monkeypox Vaccine and Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added toResearchAndMarkets.com's offering.

The globalmonkeypox vaccine and treatment market was valued at USD 8.19 billion in 2022 and is expected to reach USD 19.68 billion in 2030, with a CAGR of 10.14% during the forecast period 2023-2030.

The report on the global monkeypox vaccine and treatment market provides qualitative and quantitative analysis for the period from 2021-2030. The study on monkeypox vaccine and treatment market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

The monkeypox vaccine and treatment market refer to the commercial landscape associated with products and services aimed at preventing and managing monkeypox infections. This includes the development, production, and distribution of vaccines and treatments designed to mitigate the impact of monkeypox outbreaks. Companies operating in this market focus on research, manufacturing, and strategic partnerships to provide effective solutions, addressing the demand for medical interventions in regions susceptible to monkeypox infections. The market plays a crucial role in public health by offering preventive measures and therapeutic options for individuals and communities affected by monkeypox.

The increasing incidence of monkeypox, accompanied by intermittent outbreaks, serves as a notable catalyst for the market. This heightened prevalence has created a demand for effective solutions and therapeutics, driving growth and innovation within the industry. As stakeholders seek to address the challenges posed by these outbreaks, opportunities for research, development, and market expansion are on the rise. The urgency to combat and manage monkeypox has propelled investment and initiatives, positioning the market to play a pivotal role in public health and safety.

The injectables segment stands out as the fastest-growing category in the monkeypox vaccine and treatment market. This notable growth is attributed to various factors such as the efficacy and rapid response associated with injectable formulations. As the demand for effective monkeypox prevention and treatment options rises, the injectables segment gains prominence due to its convenience, efficiency, and potential for widespread application. This trend underscores the increasing importance of injectable solutions in addressing the challenges posed by monkeypox, contributing significantly to the overall expansion and advancement of the market.

North America is poised to hold the most prominent market share. This prominence can be attributed to the region's robust healthcare infrastructure, advanced research capabilities, and strategic investments in the field of infectious disease management. The heightened awareness and proactive approach of North American healthcare authorities in addressing emerging health threats further contribute to this dominance.

Additionally, collaborations between pharmaceutical companies, research institutions, and government agencies in North America are fostering innovation and accelerating the development of effective monkeypox vaccines and treatments. The region's pivotal market position signifies lucrative opportunities for industry players and underscores its commitment to tackling public health challenges with cutting-edge solutions.

Report Findings

Drivers

Restraints

Opportunities

Company Profiles

The companies covered in the report include

Segment Covered

The Global Monkeypox Vaccine and Treatment Market by Product

The Global Monkeypox Vaccine and Treatment Market by Gender

The Global Monkeypox Vaccine and Treatment Market by Route of Administration

The Global Monkeypox Vaccine and Treatment Market by End-use

For more information about this report visit https://www.researchandmarkets.com/r/l8oifj

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

More:

Global Monkeypox Vaccine and Treatment Analysis Report 2024: Market to Reach $19.68 Billion by 2030, Driven by ... - PR Newswire

More than 3,700 cases of mpox have been identified in the UK since May 2022

The National Institute for Health and Care Research (NIHR) has announced a new phase 1/2 trial, delivered by the NIHR Clinical Research Network and sponsored by Moderna, to test the effectiveness of an investigational mRNA vaccine for mpox.

The mPower trial will evaluate the safety and immune response to mRNA-1769, which aims to protect against illness caused by the mpox virus.

Currently a global public health threat, mpox is an infectious disease caused by the monkeypox virus, which is spread through physical contact with someone who is infected, leading to symptoms including painful rashes, enlarged lymph nodes and fever.

Since May 2022, over 3,700 cases of mpox have been identified in the UK, the majority of which have been from the Clade II B.1 lineage, predominantly in gay, bisexual and other men who have sex with men.

In the UK and Europe, there is only one vaccine licensed for the immunisation against mpox, called Imvanex, manufactured by Bavarian Nordic, along with Jynneos in the US and Imvamune in Canada.

Undertaken as part of the Moderna-UK Strategic Partnership, the trial aims to recruit around 350 healthy participants between the ages of 18 and 49 years old who have not been previously vaccinated for mpox and who have not had a suspected or confirmed mpox infection to receive the investigational vaccine or a placebo.

Researchers from University Hospitals Bristol and Weston NHS Foundation Trust are hoping to recruit a further 175 volunteers for the study, aiming to complete enrolment by April this year.

Dr Matthew Hallsworth, NIHR Director of Strategic Partnerships, said: Our partnership with Moderna ensures UK research is at the cutting edge of new vaccine technologies with the potential to protect against global health threats such as mpox and future pandemics.

We hope that recruitment to this trial will be as successful as the COVID-19 vaccine trials that were run in the UK and we encourage the public to help out where they can.

See original here:

NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK - PharmaTimes - PharmaTimes

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email

Volunteers are being sought to test a new mRNA vaccine for mpox, formerly known as monkeypox.

The vaccine trial from the National Institute for Health and Care Research (NIHR) and pharmaceutical firm Moderna will see whether the jab can offer good protection in people who have not been previously infected.

Mpox is passed on through close physical contact, including during sexual contact, kissing, cuddling or holding hands.

Symptoms include a high temperature, headache, muscle aches, backache, swollen glands, exhaustion, joint pain and a rash.

In the UK, one vaccine is currently licensed for immunisation against mpox.

Scientists now hope to offer another choice in the form of an mRNA jab for mpox and smallpox.

Volunteers in the mPower Trial will be randomly selected to receive one of three dose levels of the vaccine, or a placebo.

The trial is recruiting people from sites across the UK and will be led by the University Hospitals Bristol and Weston NHS Foundation Trust.

Dr Rajeka Lazarus, national co-ordinating investigator for the new study, said: Mpox is a global public health threat and more vaccines are urgently needed to prevent future outbreaks.

Throughout the Covid-19 pandemic, we were overwhelmed with the generosity of volunteers who came forward to take part in a number of vaccine trials.

Without them, the advances weve seen would not have been possible. It would be fantastic to see the same support for mpox research.

A health professional shows doses of Monkeypox vaccines

(AFP or licensors)

Experts are hoping to recruit 175 volunteers to the study, who are aged 18 to 49 and who are in good health, with plans to complete enrolment in April.

Volunteers must not have been previously vaccinated for mpox or smallpox, or had a suspected or confirmed mpox infection.

In 2022, there was an outbreak of monkeypox, with the UK reporting some of the highest case numbers in Europe, mostly in men who are gay, bisexual or have sex with other men.

The numbers have now dropped, with only 16 cases of mpox reported in England this year so far.

Dr Matthew Hallsworth, NIHR director of strategic partnerships, said: Were really pleased that Moderna has chosen to run its mpox trial in the UK. This demonstrates our strength in clinical research.

Our partnership with Moderna ensures UK research is at the cutting edge of new vaccine technologies, with the potential to protect against global health threats such as mpox and future pandemics.

We hope that recruitment to this trial will be as successful as the Covid-19 vaccine trials that were run in the UK and we encourage the public to help out where they can whether thats by volunteering or encouraging others.

Harun Tulunay, a 36-year-old sexual health advocate from London, suffered from the mpox virus in June 2022.

He ended up unable to eat or drink due to lesions in his throat. He was admitted to hospital and treated with an antiviral drug, which was originally developed for smallpox.

He said: As a man living with HIV, I took part in Covid trials and other trials to help other people.

People who will participate in this trial will be part of advancing research that will maybe change lives.

Being a part of that is such a great feeling I know that from my own experience.

People can find out more at trials.modernatx.com

More here:

Volunteers needed to test new mpox vaccine - The Independent